Q4 FY26 saw revenue of $3.6m, ARR of $14.4m, and a cash balance of $15.3m after a capital raise. SOZO platform expansion continued in cancer survivorship, heart failure, and weight management, with 95% US reimbursement coverage and strong patient test growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.